In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Fluoroquinolones are a critical class of antibiotics used to treat bacterial infections.
• Emerging bacterial resistance necessitates the development of new antimicrobial agents.
• Ro 23-6240 is a novel difluoroquinolone with potential therapeutic applications.

Purpose of the Study:

• To evaluate the in vitro antibacterial activity of Ro 23-6240.
• To compare its spectrum of activity with established fluoroquinolones: norfloxacin, enoxacin, ofloxacin, and ciprofloxacin.
• To assess the frequency of spontaneous resistance and factors affecting its activity.

Main Methods:

• In vitro susceptibility testing of Ro 23-6240 against various bacterial isolates.
• Determination of Minimum Inhibitory Concentrations (MICs) for 90% of strains (MIC90).
• Comparative analysis of Ro 23-6240 activity against selected Gram-negative and Gram-positive bacteria, including beta-lactamase producers and methicillin-resistant Staphylococcus aureus.

Main Results:

• Ro 23-6240 exhibited potent activity against Enterobacteriaceae (MIC90 ≤ 0.5 µg/ml), particularly Shigella, Salmonella, E. coli, and Y. enterocolitica (MIC90 ≤ 0.12 µg/ml).
• Activity against S. aureus, including MRSA, was observed (MIC90 ≤ 1 µg/ml), while activity against Streptococcal and anaerobic species was moderate (MIC 8-16 µg/ml).
• Its overall in vitro activity was comparable to enoxacin, norfloxacin, and ofloxacin, but slightly less potent than ciprofloxacin, with low spontaneous resistance frequency.

Conclusions:

• Ro 23-6240 possesses broad-spectrum in vitro activity, including against some resistant strains.
• Its efficacy is comparable to currently used fluoroquinolones, suggesting potential as a therapeutic agent.
• Reduced activity in the presence of magnesium, similar to urine concentrations, warrants consideration for clinical use.